The Hoffman ALS Clinical Trial Awards Program supports researchers conducting biomarker-driven early trials of ALS therapies and imaging tracers to advance treatment development and care.
Funder: ALS Association
Due Dates (Anticipated): January 2027 (Letter of intent) | March 2027 (Invited full proposal)
Funding Amounts: Up to $1,000,000 over 2 or 3 years, with milestone-based payments
Summary: Supports biomarker-driven phase 1 and phase 2a trials of ALS therapies and imaging tracers.
Key Information: Full proposals are accepted by invitation only following a letter of intent.
The ALS Association’s Hoffman ALS Clinical Trial Awards Program supports early-stage clinical trials that translate promising laboratory science into new and improved treatments and care for people living with ALS. The program funds biomarker-driven phase 1 and phase 2a trials that generate safety, dosing, and biomarker data needed to move investigational therapies closer to FDA evaluation. Positive results can reduce the risk of subsequent drug development and help attract funding for larger trials.
Supported work includes novel or repurposed treatments intended to modify ALS or address its symptoms, as well as early trials of imaging tracers. Therapeutic approaches include small molecules, genetic therapies, stem cell approaches, peptides, antibodies, and antisense therapies.